Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05260567
Other study ID # 286735
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 5, 2022
Est. completion date November 8, 2023

Study information

Verified date November 2023
Source Northumbria University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Peripheral arterial disease is a common, under-treated and under-researched issue. The vast majority of these patients often have multiple issues which can be improved with targeted behavioural change interventions. NICE has recommended that supervised exercise is the mainstay of treatment for intermittent claudication (ischaemic muscle pain on walking due to blocked and narrowed arteries). However, in the vast majority of UK hospitals, this isn't undertaken, and with the issues around group-based sessions and repeated visits to hospitals, this treatment option is not available with the coronavirus pandemic. This is a single-centre randomised control trial in 60 patients with peripheral arterial disease attending the Freeman Hospital. Patients will be randomised to either an enhanced behavioural change intervention targeting multiple health behaviours vs a simple walking intervention. Also, some patients will be involved in focus groups to understand their experience of the intervention and whether it is feasible and acceptable, allowing changes to be made to the program. The primary outcome will be to assess the feasibility and acceptability of the program. We will also be assessing multiple secondary outcomes including functional capacity, quality of life, sleep quality and smoking and alcohol reduction.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date November 8, 2023
Est. primary completion date July 30, 2023
Accepts healthy volunteers No
Gender All
Age group 40 Years and older
Eligibility Inclusion Criteria: - Diagnosis of PAD confirmed by ankle-brachial index <0.90 in one or both limbs - Age >= 40 years - Able to walk distance >50m - Live in an area deemed in lowest 30% of super output area from Office of National Statistics Exclusion Criteria: - chronic limb threatening ischemia - short claudication distance <50m - severe heart disease (Grade III or IV, New York Heart Association) - severe ischemic or haemorrhagic stroke or neurodegenerative diseases - severe hypertension (systolic blood pressure of more than 180 mm Hg, and a diastolic - blood pressure of more than 100 mm Hg) - uncontrolled cardiac arrhythmias (unstable angina during the previous month and - myocardial infarction during the previous month) - a resting heart rate of more than 120 beats per minute - has already undergone angioplasty, bypass or other surgical intervention for PAD - other severe comorbid conditions preventing the ability to engage in physical activity, - inability or unwillingness to undertake the commitments of the study

Study Design


Intervention

Behavioral:
Exercise and Lifestyle Change
Patients will undergo to weekly phone call/videoconference for 12 weeks and discuss the behaviour change. They also will undergo to home-based exercise training will be performed twice a week for 12 weeks via Zoom (up to 5 patients per session). Each session will be comprised of warm-up (10 min), the main part (15 to 20 min), and cooldown (5 to 10 min). The training aims to develop resistance, aerobic and functional capacity such as getting up, walking, pulling, pushing, throwing, transferring body weight or external loads. In addition, patients will be encouraged to increase their physical activity. Patients will be provided with a Fitbit device to monitor their step count and will be recommended to increase their previous week's average step count by 10%.

Locations

Country Name City State
United Kingdom Freeman Hospital - Newcastle upon Tyne NHS trust Newcastle Upon Tyne

Sponsors (1)

Lead Sponsor Collaborator
Northumbria University

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility of the program Feasibility will be determined by calculating the rate of patient screening, eligibility, recruitment, retention at 12 weeks and adherence to the intervention (number of sessions attended and completed) post 12 weeks
Primary Acceptability of the program Patient acceptability of the intervention and study experience more broadly will be determined through semi-structured qualitative 1-2-1 interviews and/or focus groups. post 12 weeks
Secondary Six-minute walk test (6MWT) pre and post-12 weeks
Secondary Walking Impairment Questionnaire (WIQ) pre and post-12 weeks
Secondary Walking Estimated Limitation Calculated by History (WELCH) questionnaire pre and post-12 weeks
Secondary Vascular quality of life questionnaire (VascuQoL-6) pre and post-12 weeks
Secondary EuroQoL questionnaire (EQ-5D-5L). pre and post-12 weeks
Secondary Short Form Dietary Questionnaire pre and post-12 weeks
Secondary Physical activity levels (Fitbit Charge HR) pre and post-12 weeks
Secondary Sleep (Fitbit Charge HR) pre and post-12 weeks
Secondary Alcohol and tobacco use The 3-item Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) and self-reported smoking habits pre and post-12 weeks
Secondary Mental wellbeing hospital anxiety-depression score (HADS) pre and post-12 weeks
Secondary Patient activation The Patient Activation Measure (PAM®) pre and post-12 weeks
Secondary Resource utilisation The case report forms (CRF) pre and post-12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06032065 - Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD) Phase 3
Active, not recruiting NCT03987061 - MOTIV Bioresorbable Scaffold in BTK Artery Disease N/A
Recruiting NCT03506633 - Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients N/A
Active, not recruiting NCT03506646 - Dietary Nitrate Supplementation and Thermoregulation N/A
Active, not recruiting NCT04677725 - NEtwork to Control ATherothrombosis (NEAT Registry)
Recruiting NCT05961943 - RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients N/A
Recruiting NCT06047002 - Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
Completed NCT03185052 - Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach N/A
Recruiting NCT05992896 - A Study of Loco-Regional Liposomal Bupivacaine Injection Phase 4
Completed NCT04635501 - AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial N/A
Recruiting NCT04584632 - The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery N/A
Withdrawn NCT03994185 - The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease N/A
Withdrawn NCT03538392 - Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
Recruiting NCT02915796 - Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty Phase 1
Active, not recruiting NCT02900924 - Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
Completed NCT02901847 - To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities. N/A
Not yet recruiting NCT02387450 - Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication Phase 2/Phase 3
Not yet recruiting NCT02455726 - Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease N/A
Withdrawn NCT02126540 - Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries N/A
Completed NCT02384980 - Saving Life and Limb: FES for the Elderly With PAD Phase 1